Objective:
To evaluate the effectiveness of combining PRAME status with the DecisionDx-UM test for predicting metastasis in uveal melanoma.
Key Findings:
- PRAME status enhances the predictive ability of the DecisionDx-UM test for metastatic risk.
- Three-year melanoma-specific survival rates vary significantly based on PRAME status and tumor class.
- Class 2/PRAME-positive tumors have a hazard ratio of 25.3 for melanoma-specific death compared to Class 1/PRAME-negative.
Interpretation:
The findings support the integration of PRAME as an adjunct biomarker to improve risk stratification in uveal melanoma.
Limitations:
- The study is based on real-world data, which may have inherent biases.
- Further follow-up data is needed to fully evaluate the combined biomarker approach.
Conclusion:
The study confirms the long-term performance of DecisionDx-UM and the value of PRAME in enhancing metastatic risk assessment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.